Search

Your search keyword '"Wiendl, Heinz"' showing total 19 results
Start Over Author "Wiendl, Heinz" Journal frontiers in neurology
19 results on '"Wiendl, Heinz"'

1. The dilemma of neuroprotection trials in times of successful endovascular recanalization

Author

Schmidt-Pogoda, Antje, primary, Kaesmacher, Johannes, additional, Bonberg, Nadine, additional, Werring, Nils, additional, Strecker, Jan-Kolja, additional, Koecke, Mailin Hannah Marie, additional, Beuker, Carolin, additional, Gralla, Jan, additional, Meier, Raphael, additional, Wiendl, Heinz, additional, Minnerup, Heike, additional, Fischer, Urs, additional, and Minnerup, Jens, additional

Published
2024
Full Text
View/download PDF

3. SAkuraBONSAI: Protocol design of a novel, prospective study to explore clinical, imaging, and biomarker outcomes in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder receiving open-label satralizumab

Author

Bennett, Jeffrey L., primary, Fujihara, Kazuo, additional, Kim, Ho Jin, additional, Marignier, Romain, additional, O'Connor, Kevin C., additional, Sergott, Robert C., additional, Traboulsee, Anthony, additional, Wiendl, Heinz, additional, Wuerfel, Jens, additional, Zamvil, Scott S., additional, Anania, Veronica G., additional, Buffels, Regine, additional, Künzel, Thomas, additional, Lekkerkerker, Annemarie N., additional, Lennon-Chrimes, Siân, additional, and Pittock, Sean J., additional

Published
2023
Full Text
View/download PDF

4. Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies

Author

Hatchwell, Eli, primary, Smith, Edward B., additional, Jalilzadeh, Shapour, additional, Bruno, Christopher D., additional, Taoufik, Yassine, additional, Hendel-Chavez, Houria, additional, Liblau, Roland, additional, Brassat, David, additional, Martin-Blondel, Guillaume, additional, Wiendl, Heinz, additional, Schwab, Nicholas, additional, Cortese, Irene, additional, Monaco, Maria Chiara, additional, Imberti, Luisa, additional, Capra, Ruggero, additional, Oksenberg, Jorge R., additional, Gasnault, Jacques, additional, Stankoff, Bruno, additional, Richmond, Todd A., additional, Rancour, David M., additional, Koralnik, Igor J., additional, Hanson, Barbara A., additional, Major, Eugene O., additional, Chow, Christina R., additional, and Eis, Peggy S., additional

Published
2022
Full Text
View/download PDF

11. An Assay to Determine Mechanisms of Rapid Autoantibody-Induced Neurotransmitter Receptor Endocytosis and Vesicular Trafficking in Autoimmune Encephalitis

Author

Amedonu, Elsie, primary, Brenker, Christoph, additional, Barman, Sumanta, additional, Schreiber, Julian A., additional, Becker, Sebastian, additional, Peischard, Stefan, additional, Strutz-Seebohm, Nathalie, additional, Strippel, Christine, additional, Dik, Andre, additional, Hartung, Hans-Peter, additional, Budde, Thomas, additional, Wiendl, Heinz, additional, Strünker, Timo, additional, Wünsch, Bernhard, additional, Goebels, Norbert, additional, Meuth, Sven G., additional, Seebohm, Guiscard, additional, and Melzer, Nico, additional

Published
2019
Full Text
View/download PDF

16. An Enigmatic Case of Acute Mercury Poisoning: Clinical, Immunological Findings and Platelet Function

Author

Kleffner, Ilka, primary, Eichler, Susann, additional, Ruck, Tobias, additional, Schüngel, Lisa, additional, Pfeuffer, Steffen, additional, Polzer, Philipp, additional, Dittrich, Ralf, additional, Dziewas, Rainer, additional, Gross, Catharina C., additional, Göbel, Kerstin, additional, Wiendl, Heinz, additional, Kehrel, Beate E., additional, and Meuth, Sven G., additional

Published
2017
Full Text
View/download PDF

18. Treating a GAD65 Antibody-Associated Limbic Encephalitis with Basiliximab: A Case Study

Author

Widman, Guido, primary, Golombeck, Kristin, additional, Hautzel, Hubertus, additional, Gross, Catharina C., additional, Quesada, Carlos M., additional, Witt, Juri-Alexander, additional, Rota-Kops, Elena, additional, Ermert, Johannes, additional, Greschus, Susanne, additional, Surges, Rainer, additional, Helmstaedter, Christoph, additional, Wiendl, Heinz, additional, Melzer, Nico, additional, and Elger, Christian E., additional

Published
2015
Full Text
View/download PDF

19. Computed tomography hypoperfusion-hypodensity mismatch vs. automated perfusion mismatch to identify stroke patients eligible for thrombolysis.

Author

Sporns PB, Kemmling A, Meyer L, Krogias C, Puetz V, Thierfelder KM, Duering M, Lukas C, Kaiser D, Langner S, Brehm A, Rotkopf LT, Kunz WG, Beuker C, Heindel W, Fiehler J, Schramm P, Wiendl H, Minnerup H, Psychogios MN, and Minnerup J

Abstract

Background and Purpose: Automated perfusion imaging can detect stroke patients with unknown time of symptom onset who are eligible for thrombolysis. However, the availability of this technique is limited. We, therefore, established the novel concept of computed tomography (CT) hypoperfusion-hypodensity mismatch, i.e., an ischemic core lesion visible on cerebral perfusion CT without visible hypodensity in the corresponding native cerebral CT. We compared both methods regarding their accuracy in identifying patients suitable for thrombolysis., Methods: In a retrospective analysis of the MissPerfeCT observational cohort study, patients were classified as suitable or not for thrombolysis based on established time window and imaging criteria. We calculated predictive values for hypoperfusion-hypodensity mismatch and automated perfusion imaging to compare accuracy in the identification of patients suitable for thrombolysis., Results: Of 247 patients, 219 (88.7%) were eligible for thrombolysis and 28 (11.3%) were not eligible for thrombolysis. Of 197 patients who were within 4.5 h of symptom onset, 190 (96.4%) were identified by hypoperfusion-hypodensity mismatch and 88 (44.7%) by automated perfusion mismatch ( p  < 0.001). Of 22 patients who were beyond 4.5 h of symptom onset but were eligible for thrombolysis, 5 patients (22.7%) were identified by hypoperfusion-hypodensity mismatch. Predictive values for the hypoperfusion-hypodensity mismatch vs. automated perfusion mismatch were as follows: sensitivity, 89.0% vs. 50.2%; specificity, 71.4% vs. 100.0%; positive predictive value, 96.1% vs. 100.0%; and negative predictive value, 45.5% vs. 20.4%., Conclusion: The novel method of hypoperfusion-hypodensity mismatch can identify patients suitable for thrombolysis with higher sensitivity and lower specificity than established techniques. Using this simple method might therefore increase the proportion of patients treated with thrombolysis without the use of special automated software.The MissPerfeCT study is a retrospective observational multicenter cohort study and is registered with clinicaltrials.gov (NCT04277728)., Competing Interests: JM has received grants from Deutsche Forschungsgemeinschaft, Bundesministerium für Bildung und Forschung (BMBF), Else KrönerFresenius-Stiftung, EVER Pharma Jena GmbH, and Ferrer International, travel grants from Boehringer Ingelheim, and speaking fees from Bayer Vital and Chugai Pharma. MD has received honoraria for lectures from Bayer Vital and Sanofi Genzyme. Consultant for Hovid Berhad and Roche Pharma. CL received consulting and speaker’s honoraria from Biogen Idec, Bayer Schering, Bristol-Myers Squibb, Daiichi Sanykyo, Merck Serono, Novartis, Sanofi, Genzyme and TEVA. JF has received grants from German Ministry of Science and Education (BMBF), German Ministry of Economy and Innovation (BMWi), German Research Foundation (DFG), European Union (EU), Hamburgische Investitions- und Förderbank (IFB), Medtronic, Microvention, Route92, Stryker. Consultant for: Acandis, Bayer, Boehringer Ingelheim, Cerenovus, Evasc Neurovascular, MD Clinicals, Medtronic, Microvention, Penumbra, Phenox, Stryker, Transverse Medical. Stock holder: Tegus Medical. CK has received honoraria and travel grants from Bayer Vital and Daiichi-Sankyo. DK receives a grant from Else Kröner-Fresenius-Center for Digital Health. PS has received grants from Siemens and Penumbra. Consultant for: Penumbra, Phenox, Stryker, Cerus endovascular. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision., (Copyright © 2023 Sporns, Kemmling, Meyer, Krogias, Puetz, Thierfelder, Duering, Lukas, Kaiser, Langner, Brehm, Rotkopf, Kunz, Beuker, Heindel, Fiehler, Schramm, Wiendl, Minnerup, Psychogios and Minnerup.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results